Xponance Inc. Has $18.21 Million Holdings in Zoetis Inc. $ZTS

Xponance Inc. lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 14.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 124,473 shares of the company’s stock after acquiring an additional 15,768 shares during the period. Xponance Inc.’s holdings in Zoetis were worth $18,213,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of Zoetis by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock worth $6,190,326,000 after acquiring an additional 419,777 shares during the period. Geode Capital Management LLC raised its holdings in shares of Zoetis by 0.9% during the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after acquiring an additional 95,294 shares in the last quarter. Norges Bank bought a new stake in Zoetis in the second quarter valued at $809,491,000. Brown Advisory Inc. raised its holdings in Zoetis by 5.7% in the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after purchasing an additional 250,829 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after purchasing an additional 550,859 shares during the period. 92.80% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. UBS Group set a $136.00 price objective on Zoetis in a research report on Thursday, January 29th. Morgan Stanley set a $160.00 price objective on Zoetis in a research report on Thursday, December 18th. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research note on Thursday. Barclays initiated coverage on shares of Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target for the company. Finally, Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Price Performance

Shares of Zoetis stock opened at $129.65 on Friday. The firm has a market cap of $54.73 billion, a PE ratio of 21.54, a PEG ratio of 1.97 and a beta of 0.96. The stock has a 50 day moving average of $125.88 and a 200 day moving average of $134.28. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.00.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter last year, the firm earned $1.40 EPS. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.6%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.